These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

340 related items for PubMed ID: 25940371

  • 1. Synergistic antiproliferative effect of imatinib and adriamycin in platelet-derived growth factor receptor-expressing osteosarcoma cells.
    Yamaguchi SI, Ueki A, Sugihara E, Onishi N, Yaguchi T, Kawakami Y, Horiuchi K, Morioka H, Matsumoto M, Nakamura M, Muto A, Toyama Y, Saya H, Shimizu T.
    Cancer Sci; 2015 Jul; 106(7):875-82. PubMed ID: 25940371
    [Abstract] [Full Text] [Related]

  • 2. Platelet-derived growth factor receptor as a prognostic marker and a therapeutic target for imatinib mesylate therapy in osteosarcoma.
    Kubo T, Piperdi S, Rosenblum J, Antonescu CR, Chen W, Kim HS, Huvos AG, Sowers R, Meyers PA, Healey JH, Gorlick R.
    Cancer; 2008 May 15; 112(10):2119-29. PubMed ID: 18338812
    [Abstract] [Full Text] [Related]

  • 3. Increased sensitivity to the platelet-derived growth factor (PDGF) receptor inhibitor STI571 in chemoresistant glioma cells is associated with enhanced PDGF-BB-mediated signaling and STI571-induced Akt inactivation.
    Servidei T, Riccardi A, Sanguinetti M, Dominici C, Riccardi R.
    J Cell Physiol; 2006 Jul 15; 208(1):220-8. PubMed ID: 16575905
    [Abstract] [Full Text] [Related]

  • 4. Imatinib mesylate inhibits platelet-derived growth factor receptor phosphorylation of melanoma cells but does not affect tumorigenicity in vivo.
    McGary EC, Onn A, Mills L, Heimberger A, Eton O, Thomas GW, Shtivelband M, Bar-Eli M.
    J Invest Dermatol; 2004 Feb 15; 122(2):400-5. PubMed ID: 15009722
    [Abstract] [Full Text] [Related]

  • 5. Imatinib as a key inhibitor of the platelet-derived growth factor receptor mediated expression of cell surface heparan sulfate proteoglycans and functional properties of breast cancer cells.
    Malavaki CJ, Roussidis AE, Gialeli C, Kletsas D, Tsegenidis T, Theocharis AD, Tzanakakis GN, Karamanos NK.
    FEBS J; 2013 May 15; 280(10):2477-89. PubMed ID: 23374223
    [Abstract] [Full Text] [Related]

  • 6. Selective inhibition of PDGFR by imatinib elicits the sustained activation of ERK and downstream receptor signaling in malignant glioma cells.
    Dong Y, Jia L, Wang X, Tan X, Xu J, Deng Z, Jiang T, Rainov NG, Li B, Ren H.
    Int J Oncol; 2011 Feb 15; 38(2):555-69. PubMed ID: 21152856
    [Abstract] [Full Text] [Related]

  • 7. Imatinib mesylate inhibits cell invasion of malignant peripheral nerve sheath tumor induced by platelet-derived growth factor-BB.
    Aoki M, Nabeshima K, Koga K, Hamasaki M, Suzumiya J, Tamura K, Iwasaki H.
    Lab Invest; 2007 Aug 15; 87(8):767-79. PubMed ID: 17558420
    [Abstract] [Full Text] [Related]

  • 8. Inhibition of platelet-derived growth factor receptor phosphorylation by STI571 (Gleevec) reduces growth and metastasis of human pancreatic carcinoma in an orthotopic nude mouse model.
    Hwang RF, Yokoi K, Bucana CD, Tsan R, Killion JJ, Evans DB, Fidler IJ.
    Clin Cancer Res; 2003 Dec 15; 9(17):6534-44. PubMed ID: 14695158
    [Abstract] [Full Text] [Related]

  • 9. Combination therapy using imatinib and vatalanib improves the therapeutic efficiency of paclitaxel towards a mouse melanoma tumor.
    Kłosowska-Wardęga A, Hasumi Y, Åhgren A, Heldin CH, Hellberg C.
    Melanoma Res; 2011 Feb 15; 21(1):57-65. PubMed ID: 20975605
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Hypoxia- or PDGF-BB-dependent paxillin tyrosine phosphorylation in pulmonary hypertension is reversed by HIF-1α depletion or imatinib treatment.
    Veith C, Zakrzewicz D, Dahal BK, Bálint Z, Murmann K, Wygrecka M, Seeger W, Schermuly RT, Weissmann N, Kwapiszewska G.
    Thromb Haemost; 2014 Dec 15; 112(6):1288-303. PubMed ID: 25231004
    [Abstract] [Full Text] [Related]

  • 14. Metronomic scheduling of imatinib abrogates clonogenicity of neuroblastoma cells and enhances their susceptibility to selected chemotherapeutic drugs in vitro and in vivo.
    Palmberg E, Johnsen JI, Paulsson J, Gleissman H, Wickström M, Edgren M, Ostman A, Kogner P, Lindskog M.
    Int J Cancer; 2009 Mar 01; 124(5):1227-34. PubMed ID: 19058199
    [Abstract] [Full Text] [Related]

  • 15. The dermatofibrosarcoma protuberans-associated collagen type Ialpha1/platelet-derived growth factor (PDGF) B-chain fusion gene generates a transforming protein that is processed to functional PDGF-BB.
    Shimizu A, O'Brien KP, Sjöblom T, Pietras K, Buchdunger E, Collins VP, Heldin CH, Dumanski JP, Ostman A.
    Cancer Res; 1999 Aug 01; 59(15):3719-23. PubMed ID: 10446987
    [Abstract] [Full Text] [Related]

  • 16. Potential roles of growth factor PDGF-BB in the bony repair of injured growth plate.
    Chung R, Foster BK, Zannettino AC, Xian CJ.
    Bone; 2009 May 01; 44(5):878-85. PubMed ID: 19442606
    [Abstract] [Full Text] [Related]

  • 17. Activation of the platelet-derived growth factor-receptor enhances survival of murine bone endothelial cells.
    Langley RR, Fan D, Tsan RZ, Rebhun R, He J, Kim SJ, Fidler IJ.
    Cancer Res; 2004 Jun 01; 64(11):3727-30. PubMed ID: 15172974
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor).
    Heinrich MC, McArthur GA, Demetri GD, Joensuu H, Bono P, Herrmann R, Hirte H, Cresta S, Koslin DB, Corless CL, Dirnhofer S, van Oosterom AT, Nikolova Z, Dimitrijevic S, Fletcher JA.
    J Clin Oncol; 2006 Mar 01; 24(7):1195-203. PubMed ID: 16505440
    [Abstract] [Full Text] [Related]

  • 20. Synergistic effects of imatinib and carboplatin on VEGF, PDGF and PDGF-Rα/ß expression in squamous cell carcinoma of the head and neck in vitro.
    Schultz JD, Rotunno S, Riedel F, Anders C, Erben P, Hofheinz RD, Faber A, Thorn C, Sommer JU, Hörmann K, Sauter A.
    Int J Oncol; 2011 Apr 01; 38(4):1001-12. PubMed ID: 21249316
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.